Exclusion criteria were significant non-HIV medical disease, schizophrenia, bipolar disorder, contraindication to
imipramine, current substance abuse, significant cognitive impairment (Mini-Mental State Examination8 score < 25), inability to speak English, and concurrent psychiatric treatment aside from HIV self - help or support
groups.
Subjects randomized to the SWI
group (n = 26) received a mean
imipramine dosage of 210 ± 66 mg / d (n = 23; range, 50 - 300 mg / d), with a mean
imipramine / desipramine blood level of 177 ± 76 mg / dL (n = 18; range, 54 - 339 mg / dL).